monoamine oxidase b

Monoamine Oxidase B inhibitor 2 is a potent, reversible, orally active and selective inhibitor of monoamine oxidase B (MAO-B) (IC50 = 1.33 nM) which can across the blood-brain barrier (BBB). Monoamine Oxidase B inhibitor 2 shows antioxidant and anti-neuroinflammatory activities which can be used in the study of Parkinson’s disease [1].

Monoamine Oxidase B inhibitor 1 is a potent, reversible, orally active and selective monoamine oxidase B (MAO-B) inhibitor (IC50 = 0.02 nM) that can across the blood-brain barrier (BBB). Monoamine Oxidase B inhibitor 1 shows antioxidant and anti-neuroinflammatory activities that can be used in the study of Parkinson’s disease[1].

Monoamine oxidase/Aromatase-IN-1 (compound 2q) is a potent dual inhibitor of monoamine oxidase (MAO) and aromatase, with IC50 values of 39 nM and 31 nM for MAO-B and aromatase, respectively. It holds significant potential for research in neurological disorders and breast cancer [1].

Monoamine oxidase, an enzyme comprising various polypeptides, catalyzes the oxidative deamination of diverse biological amines within both brain and peripheral tissues, yielding hydrogen peroxide in the process. This enzyme is crucial for regulating synaptic transmission, emotional behavior, and other cerebral functions [1] [2].

MAO-B-IN-9 is a monoamine oxidase B MAO-B inhibitor (IC50: 0.18 μM) that crosses the blood-brain barrier with potency, selectivity and time-dependence. MAO-B-IN-9 has neuroprotective effects against Aβ1-42-induced neuronal cell death, which may be related to the anti-aggregation effect of Aβ1-42.

hMAO-B-IN-5 is a potent reversible and selective human monoamine oxidase hMAO-B inhibitor (IC50:0.12μM). hMAO-B-IN-5 can cross the blood-brain barrier and can be used in the study of Parkinson's disease. It is a promising compound in the treatment and diagnosis of central nervous system diseases.

Desoxypeganine (Deoxypeganine) is an inhibitor of cholinesterase. It acting preferentially on butyrylcholinesterase, and as a selective inhibitor of monoamine oxidase A but not monoamine oxidase B.Desoxypeganine is being developed for its potential utility in the pharmacological treatment of alcohol abuse to reduce craving and depression in alcohol abusers, and might also be useful as a smoking cessation aid.

Ladostigil (Ladostigil free base) is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO) with inhibitory effects on MAO-B and AChE, with IC50 values of 37.1 and 31.8 μM, respectively.Ladostigil possesses anti-inflammatory, antioxidant, and neuroprotective activities, and may be used in studies of depression and Alzheimer's disease.

Bazinaprine is a selective, reversible monoamine oxidase inhibitor (MAOI) that is a candidate compound for the treatment of depression. Bazinaprine showed strong inhibitory effect on type A monoamine oxidase and weak inhibitory effect on type b monoamine oxidase. Bazinaprine is reversible in vivo, but not in vitro.

PSB-1434 is a selective and competitive monoamine oxidase B inhibitor.

FCE 28073 is a Monoamine oxidase B inibitor with IC50 of 0.45 uM.

PSB-1491 is a selective and competitive monoamine oxidase B inhibitor with IC50 of 0.386 nM, >25000-fold selective versus MAO-A.

MAO-B-IN-1 is a monoamine oxidase B inhibitor and can be used for the research of neurological diseases.

β-Aminopropionitrile (3-Aminopropionitrile) is a selective inhibitor of lysyl oxidase.

J-147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging. It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated in the pathogenesis of diabetic neuropathy.

Jatrorrhizine (neprotin) is a protoberberine alkaloid isolated from Enantia chlorantha (Annonaceae) and other species. It was found to have antimicrobial and antifungal activity. It binds and noncompetitively inhibits monoamine oxidase (IC50 4 micromolar for MAO-A and 62 for MAO-B).

Pargyline (Pargylamine) is a monoamine oxidase inhibitor with antihypertensive properties.

Harmane (Loturine) is a bio-active β-Carboline and monoamine oxidase inhibitor found in coffee and tobacco smoke.

PF-9601N showed high potency and selectivity as a MAO-BI (monoamine oxidase type B inhibitor) and also demonstrated remarkable neuroprotective properties in several in vivo and cellular models of PD.

WAY-620147 is a derivative of N-(2-morpholinoethyl)nicotinamide, which is able to inhibit Monoamine Oxidase.WAY-620147 has an IC50 value of 26 μM for MAO-A and 55 μM for MAO-B, and can be used for the study of neurological diseases.

2'-O-Methylperlatolic acid and confluentic acid are monoamine oxidase B inhibitors in a Brazilian plant, Himatanthus sucuuba.

Cudraflavone B has anti-proliferative activity, mouse brain monoamine oxidase (MAO) inhibitory effects, apoptotic actions in human gastric carcinoma cells and mouse melanoma cells, and hepatoprotective activity. It may be a lead for the development of a potential candidate for human oral squamous cell carcinoma cells.

MAO-B-IN-27 (Compound 12c), a monoamine oxidase B (MAO-B) inhibitor, exhibits a potent and selective inhibitory effect on hMAO-B, with an IC50 value of 8.9 nM, and is utilized in Parkinson's disease (PD) research [1].

Budipine is a low affinity, N-methyl-D-aspartate receptor antagonist,is an antiparkinsonian agent.

Bifemelane hydrochloride is a MAO inhibitor

MAO-IN-3 (Compound 5), a reversible and competitive monoamine oxidase (MAO) inhibitor with inhibition constants (K i) of 0.6 μM for MAO A and 0.2 μM for MAO B, effectively suppresses LN-229 glioblastoma cell proliferation, as denoted by an inhibitory concentration (IC50) of 0.8 μM. This compound holds potential application in cancer research [1].

ETAP, a dual inhibitor of both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B), exhibits antidepressant-like effects and is utilized in the research of major depressive disorder [1].

Pargyline hydrochloride (Pargylamine hydrochloride) is an irreversible monoamine oxidase(MAO) inhibitor with antihypertensive properties.

SL-25.1188 is a monoamine oxidase B (MAO-B) inhibitor. SL-25.1188 is characterized by reversible binding, high brain uptake, and very slow plasma metabolism in vivo.

Resveratrol is a potent phenolic antioxidant found in grapes, red wine, and various berries that also has antiproliferative and anti-inflammatory activity. cis-Resveratrol is the double bond isomer of trans-resveratrol, the more often studied and naturally abundant of the two resveratrol isomers. cis-Resveratrol exhibits antioxidant activity in the µM range similar to that observed with trans-resveratrol. It blocks production of reactive oxygen species (ROS) by inhibition of NAD(P)H oxidase and also inhibits production of nitric oxide. At a concentration of 100 µM, cis-resveratrol significantly inhibits the expression of genes related to the Rel/NF-κB/IκB family, adhesion molecules, and acute-phase proteins in LPS and INF-γ-stimulated murine peritoneal macrophages. cis-Resveratrol inhibits uptake of noradrenaline and 5-HT by synaptosomes from rat brain with IC50 values of 79 and 51 µM, respectively. It also inhibits human monoamine oxidase-A (MOA-A) and MOA-B with IC50 values of 25 and 61 µM, respectively, which is similar to, but slightly less effective than, values obtained with trans-resveratrol.

AChE/MAO-IN-1 is a potent inhibitor of human acetylcholinesterase (AChE), monoamine oxidase A (MAO-A), and monoamine oxidase B (MAO-B), demonstrating inhibitory concentrations (IC50) of 0.0248 μM, 0.0409 μM, and 0.1108 μM against AChE, MAO-A, and MAO-B, respectively.

FTEAA, a 4-styrylpiperidine inhibitor, effectively inhibits monoamine oxidase (MAO), displaying IC50 values of 0.52 μM (MAO-A) and 1.02 μM (MAO-B). Its potent activity suggests potential application in research related to cardiovascular, neurological, and oncological disorders.

MAO-B inhibitor 58 is an effective, selective, and reversible inhibitor of monoamine oxidase B.

Ladostigil hemitartrate (TV-3326) is a compound that acts as a dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO). It has IC50 values of 37.1 μM for MAO-B and 31.8 μM for AChE. In addition, Ladostigil hemitartrate possesses neuroprotective, antioxidant, and anti-inflammatory properties. It is commonly used in research relating to depression and Alzheimer's disease.

MAO-B-IN-11, also known as Compound 8c, is a highly potent inhibitor of monoamine oxidase B (MAO-B), with an IC50 value of 1.3 μM. Additionally, MAO-B-IN-11 exhibits neuroprotective properties [1].

Norharmane (β-Carboline) is a natural β-carboline first isolated from plants of the Zygophyllaceae family.

MAO-B-IN-25 (compound 92) is a selective inhibitor of monoamine oxidase B (MAO-B), exhibiting inhibitory half-maximal inhibitory concentrations (IC50) of 240 nM for MAO-B and 0.5 nM for MAO-A [1].

PSB-1410 is a selective and competitive monoamine oxidase B inhibitor.

AChE/BChE/MAO-B-IN-3, an indan-1-one derivative, serves as a potent inhibitor of human monoamine oxidase B (MAO-B) with an IC50 of 0.0359 μM, demonstrating significant inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values of 0.0473 μM and 0.0782 μM, respectively. Exhibiting notable antioxidant activity, AChE/BChE/MAO-B-IN-3 holds considerable promise for Alzheimer's disease (AD) research.

AChE/BChE/MAO-B-IN-4, an indan-1-one derivative, serves as a potent inhibitor for both monoamine oxidase B (MAO-B) and acetylcholinesterase/butyrylcholinesterase (AChE/BChE) enzymes. It exhibits a strong inhibitory effect on human MAO-B with an IC50 of 0.0393 μM, and demonstrates significant potency against human AChE and BChE enzymes with IC50 values of 0.0458 μM and 0.075 μM, respectively. Additionally, this compound displays notable antioxidant properties and the ability to prevent β-amyloid plaque aggregation, marking its potential utility in Alzheimer's disease (AD) research.

CAY10680 is a dopamine-sparing, benzothiazinone compound that selectively inhibits both MAO-B activity (IC50 = 34.9 nM in human) and adenosine A2A receptors (Ki = 39.5 nM in human). It demonstrates significantly less potent inhibitory values for other adenosine receptor subtypes (Kis > 1 μM) and MAO-A (IC50 ≥ 10 μM). At 1-20 μM, CAY10680 has been shown to abolish cAMP accumulation in CHO cells transfected with adenosine A2A receptors. In the central nervous system adenosine A2A receptor expression is localized to dopamine-innervated areas where heteromeric complexes are formed with dopamine D2 receptors. Because inhibition of adenosine A2A receptors has been shown to enhance D2 receptor function, the blockade of adenosine A2A receptors has emerged as a potential treatment for Parkinson's disease. An additional strategy in the treatment of Parkinson's disease has been to block the activity of monoamine oxidase B (MAO-B), the enzyme involved in dopamine catabolism.

5-Hydroxy-1-methoxyxanthone, 1,5-dihydroxyxanthone and 6-deoxyjacareubin are all antifungal against Cladosporium cucumerinum, while they show differing degrees of inhibition of monoamine oxidase A and B.

MAO-B-IN-17 is a selective and potent monoamine oxidase B (MAO-B) inhibitor (IC50: 5.08 μM) for the study of central nervous system disorders like Parkinson's.

Methyl citrate, obtained from Opuntia ficus-indica var. saboten Makino fruits, serves as a potent Monoamine oxidase B (MAO-B) inhibitor with an IC50 value of 0.23 mM.

MAO-B-IN-16 is a selective inhibitor of monoamine oxidase B (MAO-B ) (IC 50 = 1.55 μM) that can be used in the central nervous disorders study, for example, parkinson's disease [1].

MAO-B-IN-3 is a reversible, selective inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 96 nM and demonstrates affinity for the 5-HT6 receptor with a Ki of 696 nM, making it suitable for Alzheimer's disease research [1].

MAO-B-IN-4 (Compound 26) is a reversible monoamine oxidase B (MAO-B) inhibitor with potent in vitro activity, characterized by an IC50 value of 9 nM. This orally active compound exhibits favorable metabolic stability, a satisfactory safety profile, and effective brain permeability. Demonstrating antidepressant effects in rodent models, MAO-B-IN-4 is suitable for research into Alzheimer's disease [1].

IHC3 is a competitive and reversible monoamine oxidase B (MAO-B) inhibitor with an IC50 of 1.672 μM, which targets Cys172 within the enzyme's active site. It is utilized in the study of neurological diseases [1].

Rosiridin (6'-O-Deacetylrosiridoside C) has cardioprotective activity.

Pirlindole-d4 is intended for use as an internal standard for the quantification of pirlindole by GC- or LC-MS. Pirlindole is a selective and reversible monoamine oxidase A (MAO-A) inhibitor. It is selective for MAO-A over MAO-B. In rats, it reverses the depressive-like effects induced by chronic mild stress (CMS), increases proliferation of hippocampal neural progenitor cells, and reverses dendritic atrophy in granule neurons. Pirlindole is also an inhibitor of enterovirus-D68 and coxsackievirus B3 (CV-B3), inhibiting the genome replication phase of CV-B3 infection with an EC50 value of 7.7 µM independent of MAO-A activity.